Objective: The objective was to describe the methodology used to develop new response criteria for adult DM/PM and JDM. Methods: Patient profiles from prospective natural history data and clinical trials were rated by myositis specialists to develop consensus gold-standard ratings of minimal, moderate and major improvement. Experts completed a survey regarding clinically meaningful improvement in the core set measures (CSM) and a conjoint-analysis survey (using 1000Minds software) to derive relative weights of CSM and candidate definitions. Six types of candidate definitions for response criteria were derived using survey results, logistic regression, conjoint analysis, application of conjoint-analysis weights to CSM and published definitions. Sensitivity, specificity and area under the curve were defined for candidate criteria using consensus patient profile data, and selected definitions were validated using clinical trial data. Results: Myositis specialists defined the degree of clinically meaningful improvement in CSM for minimal, moderate and major improvement. The conjoint-analysis survey established the relative weights of CSM, with muscle strength and Physician Global Activity as most important. Many candidate definitions showed excellent sensitivity, specificity and area under the curve in the consensus profiles. Trial validation showed that a number of candidate criteria differentiated between treatment groups. Top candidate criteria definitions were presented at the consensus conference. Conclusion: Consensus methodology, with definitions tested on patient profiles and validated using clinical trials, led to 18 definitions for adult PM/DM and 14 for JDM as excellent candidates for consideration in the final consensus on new response criteria for myositis.

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects / L.G. Rider, N. Ruperto, A. Pistorio, B. Erman, N. Bayat, P.A. Lachenbruc, H. Rockette, B.M. Feldman, A.M. Huber, P. Hansen, C.V. Oddis, I.E. Lundberg, A.A. Amato, H. Chinoy, R.G. Cooper, L. Chung, K. Danko, D. Fiorentino, I.G. De la Torre, A.M. Reed, Y.W. Song, R. Cimaz, R.J. Cuttica, C.A. Pilkington, A. Martini, J. van der Net, S. Maillard, F.W. Miller, J. Vencovsky, R. Aggarwal, L. Christopher-Stine, L. Criscione-Schreiber, L. Crofford, M.E. Cronin, P. Gordon, G. Hengstman, J.D. Katz, A. Mammen, G. Marder, N. Mchugh, E. Schiopu, G. Wolfe, R. Wortmann, M. Apaz, S. Bowyer, T. Constantin, M. Curran, J. Davidson, T. Griffin, O. Jones, S. Kim, B. Lang, C. Lindsley, D. Lovell, C.S. Magalhaes, L.M. Pachman, A. Ponyi, M. Punaro, P. Quartier, A.V. Ramanan, A. Ravelli, R. Rennebohm, A. Van Royen-Kerkhof, D.D. Sherry, C.A. Silva, E. Stringer, C. Wallace, D. Ascherman, R. Barohn, O. Benveniste, J. De Bleecker, J. Callen, C. Charles-Schoeman, S. Danoff, M. Dastmalchi, M. Dimachkie, S. Di Martino, L. Dourmishev, F. Ernste, T. Gono, D. Isenberg, Y. Katsumata, J. Kissel, R.L. Leff, T. Levine, H. Mann, I. Marie, J. Merola, M. Olesinska, N. Olsen, N. Pipitone, S. Ramchandren, S. Rutkove, L.A. Saketkoo, A. Schiffenbauer, A. Selva-O'Callaghan, S.K. Shinjo, R. Shupak, K. Swierkocka, M. de Visser, J. Wanschitz, V.P. Werth, I. Whitt, S. Ytterberg, T. Avcin, M. Becker, M.W. Beresford, F. Dressler, J. Dvergsten, V.P.L. Ferriani, B. Flato, V. Gerloni, M. Henrickson, C. Hinze, M. Hoeltzel, M. Ibarra, N. Ilowite, L. Imundo, D. Kingsbury, B. Magnusson, S. Maguiness, P. Mathiesen, L. Mccann, S. Nielsen, S.K.F. de Oliveira, M. Passo, E. Rabinovich, R. Rivas-Chacon, A.B. Robinson, K. Rouster-Stevens, R. Russo, L. Rutkowska-Sak, A. Sallum, H. Sanner, H. Schmeling, D. Selcen, B. Shaham, C.H. Spencer, R. Sundel, M. Tardieu, A. Thatayatikom, D. Wahezi, F. Zulian. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 56:11(2017), pp. 1884-1893. [10.1093/rheumatology/kex226]

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects

R. Cimaz;
2017

Abstract

Objective: The objective was to describe the methodology used to develop new response criteria for adult DM/PM and JDM. Methods: Patient profiles from prospective natural history data and clinical trials were rated by myositis specialists to develop consensus gold-standard ratings of minimal, moderate and major improvement. Experts completed a survey regarding clinically meaningful improvement in the core set measures (CSM) and a conjoint-analysis survey (using 1000Minds software) to derive relative weights of CSM and candidate definitions. Six types of candidate definitions for response criteria were derived using survey results, logistic regression, conjoint analysis, application of conjoint-analysis weights to CSM and published definitions. Sensitivity, specificity and area under the curve were defined for candidate criteria using consensus patient profile data, and selected definitions were validated using clinical trial data. Results: Myositis specialists defined the degree of clinically meaningful improvement in CSM for minimal, moderate and major improvement. The conjoint-analysis survey established the relative weights of CSM, with muscle strength and Physician Global Activity as most important. Many candidate definitions showed excellent sensitivity, specificity and area under the curve in the consensus profiles. Trial validation showed that a number of candidate criteria differentiated between treatment groups. Top candidate criteria definitions were presented at the consensus conference. Conclusion: Consensus methodology, with definitions tested on patient profiles and validated using clinical trials, led to 18 definitions for adult PM/DM and 14 for JDM as excellent candidates for consideration in the final consensus on new response criteria for myositis.
1000Minds software; Conjoint analysis; Dermatomyositis; Hybrid measure; Juvenile dermatomyositis; Outcome assessment; Polymyositis; Response criteria; Area Under Curve; Dermatomyositis; Humans; Logistic Models; Minimal Clinically Important Difference; Polymyositis; Treatment Outcome; Rheumatology; Pharmacology (medical)
Settore MED/16 - Reumatologia
Settore MED/38 - Pediatria Generale e Specialistica
2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
kex226.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 250.58 kB
Formato Adobe PDF
250.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/666561
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact